Annovis Bio Inc. Advances Phase 3 Alzheimer’s Trial and Reports Q2 2025 Financial Results

Annovis Bio Inc. (NYSE: ANVS), a company focused on developing therapies for neurodegenerative diseases, has reported its second-quarter 2025 results alongside updates on its corporate and clinical progress. The company's Phase 3 trial for early Alzheimer’s disease, identified by the clinical trial number NCT06709014, has now secured 76 sites across the U.S., with 46 actively enrolling patients. To date, 38 patients have been dosed, and nearly 200 are in the screening phase, with enrollment progressing as planned and a screen failure rate of 50%, which aligns with expectations.

Recent achievements by Annovis Bio include the presentation of four scientific posters at the AAIC 2025 conference, the appointment of a director of biostatistics, and the hosting of a webcast to provide updates on the trial. Additionally, the company has strengthened its intellectual property portfolio by securing global coverage for crystal buntanetap, a key component in its therapeutic pipeline.

Financially, Annovis Bio reported cash and equivalents of $17.1 million as of June 30, 2025, an increase from $10.6 million at the end of 2024. The company's research and development expenses for the quarter were $5.2 million, down from $5.8 million in the same period the previous year, while general and administrative expenses decreased to $1.1 million from $2.0 million. The net loss per share improved to $0.32 from $0.44, reflecting the company's ongoing efforts to streamline operations and focus on its core mission of addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s.

For more detailed information on Annovis Bio's recent developments and financial performance, visit https://ibn.fm/iO1TH.